Key statistics
As of last trade, RAPT Therapeutics Inc (0RA:DEU) traded at 1.08, 13.09% above the 52 week low of 0.955 set on Nov 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.02 |
---|---|
High | 1.12 |
Low | 1.02 |
Bid | 1.06 |
Offer | 1.09 |
Previous close | 1.03 |
Average volume | 2.93k |
---|---|
Shares outstanding | 34.96m |
Free float | 34.32m |
P/E (TTM) | -- |
Market cap | 37.75m USD |
EPS (TTM) | -2.78 USD |
Data delayed at least 15 minutes, as of Nov 25 2024.
More ▼
Announcements
- RAPT Therapeutics Reports Third Quarter 2024 Financial Results
- Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
- RAPT Therapeutics Reports Second Quarter 2024 Financial Results
- RAPT Therapeutics Reports First Quarter 2024 Financial Results
- RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
- RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
- RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
- RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
- RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
More ▼